Endologix to Present at the 25th Annual ROTH Conference

Endologix to Present at the 25th Annual ROTH Conference

IRVINE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc.
(Nasdaq:ELGX), developer and marketer of innovative treatments for aortic
disorders, announced today that John McDermott, President and Chief Executive
Officer and Shelley Thunen, Chief Financial Officer, are scheduled to present
at the 25th Annual ROTH Conference in Laguna Niguel, CA.

  Event: 25th Annual ROTH Conference 

  Date: Monday, March 18, 2013

  Time: 10:30 a.m. PT / 1:30 p.m. ET

An audio webcast of the Company's presentation will be available by visiting
the investor relations section of Endologix's website at www.endologix.com. A
replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for
aortic disorders. Endologix focus is endovascular stent grafts for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall
of the aorta, the largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if left
untreated, becomes increasingly susceptible to rupture. The overall patient
mortality rate for ruptured AAA is approximately 75%, making it a leading
cause of death in the U.S. Additional information can be found on Endologix's
website at www.endologix.com.

CONTACT: COMPANY CONTACT:
         Endologix, Inc.
         John McDermott, CEO
         Shelley Thunen, CFO
         (949) 595-7200
         www.endologix.com
        
         INVESTOR CONTACTS:
         The Ruth Group
         Nick Laudico (646) 536-7030
        
         Zack Kubow (646) 536-7020